RecruitingNCT06492031

Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

Effectiveness and Safety of Icodextrin Peritoneal Dialysis Solution (Extraneal®) for Long Dwell Exchange in Peritoneal Dialysis in Patients With Chronic Renal Failure: a Multicenter, Ambispective Cohort, Observational, Real-world Study

Sponsor

Vantive Health LLC

Enrollment

889 participants

Start Date

Jun 28, 2024

Study Type

OBSERVATIONAL

Conditions

Chronic Renal Failure

Summary

The purpose of this study is to evaluate the effectiveness and safety of icodextrin and glucose peritoneal dialysis (PD) solutions for the long dwell exchange in PD patients with continuous ambulatory peritoneal dialysis (CAPD), and to describe medical resource utilization in patients with PD on icodextrin.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is examining how a peritoneal dialysis solution called icodextrin (brand name Extraneal) is used in real-world practice for people with chronic kidney failure on peritoneal dialysis (a type of dialysis done at home using the lining of the abdomen to filter waste from the blood). **You may be eligible if...** - You are 18 or older with chronic kidney failure and have been on peritoneal dialysis for at least 3 months - You have been or are being treated with icodextrin as part of your dialysis - You consent to participate and are willing to attend follow-up visits **You may NOT be eligible if...** - You have not been on peritoneal dialysis for at least 3 months - You are unable or unwilling to provide informed consent - You have not received icodextrin as part of your dialysis prescription Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIcodextrin Peritoneal Dialysis Solution

The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.

DRUGGlucose Peritoneal Dialysis Solution

The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.